CAMBRIDGE, Mass.--(BUSINESS WIRE)--Metamark Genetics, Inc. (“Metamark” or the “Company”), a leader in commercializing high value urologic oncology products, announced today that Peter Maimonis, Ph.D., has joined Metamark’s leadership team as Senior Vice President and Chief Science Officer, effective October 7, 2015.
“With his accomplished background in the discovery and development of oncology biomarkers, companion diagnostics, and assays, Peter Maimonis will be a true asset to Metamark and our mission to make better patient outcomes possible through access to better information,” said Kenneth Weg, Metamark President and CEO. “We’re delighted to have Peter on board to further advance Metamark’s lead product, ProMark®, as well as continue to grow our comprehensive portfolio of meaningful diagnostic testing services.”
Dr. Maimonis brings extensive experience in oncology research and development, and specific proficiency in oncology biomarkers in the area of prostate cancer. He has presented at a large number of national and international scientific conferences, and published many peer-reviewed articles and abstracts on cancer biomarkers. Dr. Maimonis has held senior level positions in various areas of research and development at Ciba-Corning, Chiron Diagnostics, Bayer Diagnostics, Decision Biomarkers, and On-Q-ity, and most recently served as Vice President of Biomarker Development at Biothera, working with their novel cancer immunotherapeutic.
"Through advanced diagnostic technology and ProMark®, its leading prognostic assay, Metamark delivers substantial value to physicians and their patients facing prostate cancer," stated Dr. Maimonis. "I’m thrilled to join this world-class management and scientific leadership team, and look forward to propelling Metamark’s continued quest to effectively change patient outcomes and improve the standard of care."
Dr. Maimonis received his B.S. in Biology from MIT and his Ph.D. in Tumor Immunology from Brown University, and subsequently received his postdoctoral training at Dana Farber Cancer Institute in biomarkers for lung and breast cancer. He was also a Research Fellow at Harvard with a focus in assay development and clinical application through work with clinicians and surgeons in the area of lung cancer.
Launched in late 2014, ProMark® is the first proteomic classifier of biopsied prostate tissue to assess whether an early-stage prostate tumor is aggressive or indolent. Test results generated in Metamark’s Cambridge, Mass. CLIA-certified laboratory can aid the decision to treat the cancer aggressively or to choose a course of active surveillance.
Metamark Genetics, Inc. is a privately-held biotechnology company founded to develop novel, function-based prognostic and diagnostic tests aimed at improving cancer care. The company’s proprietary genomic and proteomic discovery platforms have led to significant discoveries in several disease areas, including prostate, bladder, colon, and breast cancers. Through the acquisition of HealthTronics Laboratory Solutions in 2013, Metamark has become a leading provider of specialty urological pathology testing services with the first fully integrated clinical model for the prostate cancer care pathway.
For more information please visit the company’s website: www.metamarkgenetics.com.
Metamark® and ProMark® are registered trademarks of Metamark Genetics, Inc.